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In this study, we compared the eﬀects of SKI-606 with Iressa, Src/Abl and EGF-R kinase inhibitors, respectively, on selected
parameters in HeLa and SiHa cervical cancer cell lines, which express E6/E7 oncoproteins of high-risk HPV types 18 and 16,
respectively.OurresultsshowthatSKI-606andIressainhibitcellproliferationandprovokeG0-G1 cellcyclearrestandreductionof
S and G2-M phase using 2 and 5μM concentrations of these inhibitors. In contrast, SKI-606 induces diﬀerentiation to an epithelial
phenotype “mesenchymal-epithelial transition”; thus SKI-606 causes a dramatic decrease in cell motility and invasion abilities of
HeLa and SiHa cancer cells, in comparison to untreated cells and Iressa-treated cells in which these parameters are only slightly
aﬀected. These changes are accompanied by a regulation of the expression patterns of E-cadherin and catenins. The molecular
pathway analysis of Src/Abl inhibitor revealed that SKI-606 blocks the phosphorylation of β-catenin and consequently converts
its role from a transcriptional regulator to a cell-cell adhesion molecule. Our ﬁndings indicate that SKI-606 inhibits signaling
pathways involved in regulating tumor cell migration and invasion genes via β-catenin alteration, suggesting that Src inhibitor, in
comparison to EGF-R, is a promising therapeutic agent for human cervical cancer.
1.Introduction
Cervical cancer is the second most common malignancy
amongstwomenworldwidewithapproximately500,000new
cases and 250,000 deaths each year estimated by the World
Health Organization. Thus, the overall 5-year-survival rate
for patients diagnosed with cervical cancer is approximately
50% and has not signiﬁcantly improved over the past two
decades. Important etiological factors in the development
of this cancer are human papillomaviruses (HPVs), as more
than 96% of cervical cancers are positive for high-risk HPVs
especially types 16, 18, 31, 33, and 35 [1–3]. Moreover,
accumulating evidence suggests that persistent infection
with these viruses is necessary for cervical precursors to
evolve into invasive carcinomas [4–7]. The E6 and E7
oncoproteins of high-risk HPVs, which are constitutively
expressed in these cancers, inactivate p53 and pRb tumour
suppressors, respectively [8]. E6 facilitates the degradation of
p53 through its association with an accessory protein, E6-
AP, a component of the ubiquitin proteolytic pathway [9].
E7 proteins of high-risk HPVs bind to Rb [10], as well as to
other pocket proteins, such as p107 and p130 [11], leading to2 Journal of Oncology
cellcyclederegulation.Thisresultsingenomicinstabilityand
hasbeenimplicatedinthetransformationandprogressionof
normal and cancerous cervical cells, respectively.
Human cervical cancers are characterized by a marked
propensity for invasion and spreading to local lymph
nodes. Several investigations indicate that both invasion and
metastasis may be critically dependent on the acquisition of
the epithelial-mesenchymal transition (EMT) process [12,
13]. At least, three coordinated processes are necessary for
invasion: (1) changes in cell-cell and cell-matrix adhesion,
(2) degradation of the extracellular matrix (ECM), and
(3) cell migration. Therefore, cell-cell adhesion proteins are
greatly involved in these processes. Several studies reported
that the E-cadherin/catenin complex and P-cadherin, of the
cell-cell adhesion family, as well as fascin, Id-1, IGF-R1, and
EGF-R genes are important regulators in the progression
of several human carcinomas including cervical [14–18]. In
contrast, earlier studies reported that Src activation induces
phenotypictraitsassociatedwithmetastaticcancercells,such
asincreasedcellinvasivenessandmotilitythusdecreasingthe
survival of numerous human cancer patients [19, 20].
To explore the role of Src/Abl inhibitor, SKI-606, as
a potential treatment for human cervical carcinomas, we
compared the eﬀect of SKI-606 with Iressa on cell pro-
liferation, cell cycle progression, diﬀerentiation, invasion,
and motility in HeLa and SiHa human cervical cancer cell
lines which express E6/E7 oncoproteins of HPV types 18
and 16, respectively. We found that SKI-606 signiﬁcantly
aﬀects these processes in comparison with Iressa at the same
concentration. These eﬀects occur through the conversion of
β-catenin’s role from a transcription regulator to a cell-cell
adhesion molecule via Src dephosphorylation.
2.MaterialsandMethods
2.1. Cell Cultures and Reagents. Human cervical cancer cell
lines HeLa and SiHa were obtained from the American Type
Tissue Culture, and maintained in DMEM (Life Technolo-
gies, Inc.) supplemented with 5% fetal bovine serum, 100
units/ml penicillin, 100μg/mL streptomycin, and 2mM L-
glutamine (Life Technologies, Inc.), and incubated at 37◦C
with 5% CO2 atmosphere.
The dual Src and Abl tyrosine kinase inhibitor SKI-606
(Wyeth Research) and Iressa (AstraZeneca) were dissolved in
DMSO (Sigma Chemical Co.), which was used as a solvent
control in all experiments at the same volume used in the
inhibitors; nevertheless, we did not observe any signiﬁcant
eﬀect of DMSO-treated cells in comparison with untreated
ones. Once cell cultures were 70% conﬂuent, they were
incubated with diﬀerent concentrations of drugs as reported
in the ﬁgure legends. All our experiments were performed in
triplicates.
2.2. Proliferation Assay. HeLa and SiHa cells were seeded in
ﬂat-bottomed 96-well plates at 1 × 104 cells per well in a
volume of 100μl of supplemented medium. Three dilutions
of SKI-606 and Iressa were added as indicated in the ﬁgure
legends and the volume was adjusted to 200μl. Eight hours
beforeharvestingontoglassﬁberﬁlters,1μCi[3H]thymidine
was added to each well. Incorporation of [3H]thymidine
was measured using a ﬁlter scintillation counter (1430
MicroBeta, Wallac).
2.3. Cell Cycle Analysis. HeLa and SiHa cells were treated
with 5μM SKI-606 and Iressa for two days. Cells were
harvested, washed, and ﬁxed and subsequently treated with
50μg/mL RNase and stained with 50μg/mL propidium
iodide for 30 minutes. Cells were analyzed in a FACSCalibur
and data were evaluated with Cell Quest and ModFitLT v3.1
software.
2.4. Cell Wounding Assay. HeLa and SiHa cervical cancer
cells were grown to conﬂuence and serum-starved for 24
hours, and ﬁnally wounded with a 2mL pipette and treated
with 5μM of SKI-606 and Iressa. Cells were examined by
light microscopy 24 and 48 hours later for the ability to
r e p o p u l a t et h ew o u n da sw e l la sf o rc e l lm i g r a t i o n .
2.5. Invasion Assay. Cell invasion was assayed in 24-well
Biocoat Matrigel invasion chambers (8μm; Becton Dick-
inson) according to the manufacturer’s protocol. Brieﬂy, 5
× 104 wild type and treated cells, with 5μM SKI-606 and
Iressa, were plated in the top chamber. The bottom chamber
contained DMEM medium. After 48 hours incubation, the
noninvasive cells were removed with a cotton swab. The
cells that migrated through the membrane and stuck to the
lower surface of the membrane were ﬁxed with methanol
and stained with hematoxylin. For quantiﬁcation, cells were
counted under a microscope in ﬁve predetermined ﬁelds.
2.6. Soft Agar Growth Assay. 5 × 103 HeLa and SiHa cells
(untreated and treated with 5μM SKI-606 and Iressa) were
placed in DMEM medium containing 0.4% agar and plated
over a layer of DMEM medium containing 0.7% agar. The
cultures were examined every 1-2 days for 3 weeks.
2.7.WesternBlotandImmunoprecipitationAnalyses. Western
blot was performed as previously described [21], for the
experiments described in this study, anti-E-cadherin, α-
catenin, β-catenin, γ-catenin, and P-cadherin monoclonal
antibodies (mAbs) (Bio/Can Scientiﬁc); antifascin mAb (sc-
21743, Santa Cruz Biotechnology Inc); anticyclin D1, cyclin
D3, Cdk6, Id-1, IGF-R1 antisera (sc-753, sc-182, sc-177, sc-
488 and sc-713, Santa, Cruz Biotechnology); anti-EGF-R
antisera (Cell Signaling); anticyclin D2 mAb (Clone DCS-
3, Sigma), anti-Cdk4 mAb (Clone DCS-35, Chemicon) and
antiactin mAb (clone C4, Roche Diagnostics) were used
for this assay. For immunoprecipitation, 300 μg of proteins
were immunoprecipitated with anti-β-catenin mAb (clone
14, Bio/Can Scientiﬁc). Immunoprecipitated samples were
thenblottedonanitrocellulosemembraneanddetectedwith
antiphosphotyrosine (clone 4G10, Upstate Biotechnology)
or anti-β-catenin mAb.
2.8. Immunoﬂuorescence Analysis. HeLa cells were seeded
and treated with/without SKI-606 and Iressa, 5μMe a c h ,
on cover-slips for 2 days at a density of 50,000-cells/35mmJournal of Oncology 3
dish. The cells were rinsed with PBS and ﬁxed with 3%
(w/v)paraformaldehydeinPBSfor5minutes,followedbyan
incubation in precooled methanol (−20◦C) for 15 minutes.
The cells were then incubated with the primary antibody
anti-E-cadherin, α-, β-, and γ-catenin (mAb) (Bio/Can
Scientiﬁc) and with 0.2% BSA in PBS, as negative controls,
for 1 hour at room temperature. After three washes with
PBS, the cells were incubated with appropriate secondary
antibody conjugated to FITC (Jackson Immunoresearch
Laboratories) for 45 minutes. Finally, the cover-slips were
washed with PBS, mounted with Airvol (Air Products
and Chemicals, Inc.), and viewed with a Zeiss Axiophot
ﬂuorescent microscope equipped with 63X plan apochromat
objectives and photographed.
3. Results
SKI-606 is a Src/Abl kinase inhibitor that was shown to have
antiproliferative eﬀects on chronic myelogenous leukemia
cells as well as breast, colon and nonsmall lung cancer cells
[22–25]; however, the eﬃcacy of SKI-606 in human cervical
cancer is still unknown. Therefore, we compared the eﬀect of
SKI-606 with Iressa, a tyrosine kinase inhibitor (TKI) of EGF
and ErbB2 receptors which is presently in phase II clinical
trial for patients with recurrent or metastatic cervical carci-
nomas [26], in HeLa and SiHa cancer cell lines. Treatment of
human cervical cancer cells for 1–4 days with 2 and 5μMo f
SKI-606 slightly increased the inhibition of cell proliferation
when compared with cells treated with Iressa and untreated
cells in both cell lines. Likewise, SKI-606, but not Iressa,
caused a signiﬁcant inhibition of cell proliferation of HeLa
and SiHa cell lines at 10μM concentrations (Figure 1 and
data not shown). To examine whether the antiproliferative
eﬀectofSKI-606andIressaonHeLaandSiHacellswaspartly
mediated via speciﬁc cell cycle arrest, we investigated cell
cycle phase distributions of SKI 606 and Iressa-treated cells
using ﬂow cytometric analysis. Results revealed that SKI-606
and Iressa (to a lesser extent) cause accumulation of cells
in the G0-G1 fraction. For instance, following exposure to
5μM SKI-606 and Iressa for 48 hours, the percentage of
G0-G1 phase cells slightly increased in HeLa and SiHa cells,
with a proportional reduction in S and G2-M phase fractions
(Figure 2(a)). To investigate possible molecular mechanisms
involved in SKI-606 and Iressa-mediated G0-G1 cell cycle
arrest, several key molecules regulating transition from the
G1 to the S cell cycle phase were examined in HeLa cells
after 48 hours of SKI-606 and Iressa-treatment, including
cyclin D1, D2 and D3 as well Cdk4 and 6. Results showed
reductions in cyclin D1, D2, and D3 as well as Cdk4 and
Cdk6 in HeLa-treated cells when compared with untreated
cells (Figure 2(b)).
We also investigated the eﬀect of SKI-606 and Iressa on
cell diﬀerentiation in HeLa and SiHa cervical cancer cells.
In the absence of treatment, HeLa and SiHa cells displayed
a ﬁbroblast-like (mesenchymal) morphology, and formed
multilayered disorganized cells. In contrast, as indicated
in Figure 3, blocking Src/Abl activity led to a considerable
phenotypic conversion from ﬁbroblast-like (mesenchymal)
to epithelial phenotype. Cells became more ﬂattened in
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Figure 1: Eﬀect of SKI-606 and Iressa on cell growth of HeLa
human cervical cancer cells. We note that cell proliferation slightly
relies on Src/Abl and EGF-R inhibitor concentrations at 2 and
5μM each; in contrast, Src/Abl inhibitor, but not EGF-R, drastically
inhibits cell proliferation of HeLa and SiHa cells (data not shown)
at 10μM. Bars, SDs of each point.
appearance, and showed an increase in cell-cell contact
in comparison with untreated cells and Iressa-treated cells
in which these parameters are only slightly aﬀected. Next,
we examined the eﬀect of SKI-606 and Iressa on colony
formation of HeLa and SiHa cells; we found that SKI-
606 signiﬁcantly blocks colony growth, in soft agar, when
compared with cells treated with Iressa and wild type cells
(Figure 4).
To evaluate the role of SKI-606 and Iressa on cell
invasion and migration abilities of human cervical cancer
cells, Matrigel invasion and wound-healing assays were
preformed. HeLa and SiHa cells were treated for 24 and
48 hours with 5μMo fS K I - 6 0 6a n dI r e s s a .A si l l u s t r a t e d4 Journal of Oncology
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Figure 2: SKI-606 and Iressa (to a lesser extent) provoke G0-G1 cell cycle arrest and reduction of S and G2-M phase of HeLa and SiHa cells.
A, propidium iodide staining shows a signiﬁcant increase (P<. 0001 and P<. 001) in the proportion of HeLa and SiHa cells, respectively,
in the G0-G1 phase of the cell cycle following 48 hours of SKI-606 and Iressa treatments (5μM). B, SKI-606, but not Iressa, treatment for 48
hours results in changes in key G0-G1 cell cycle phase regulators in HeLa cells.
in Figure 5, SKI-606 blocked cell migration and invasion
abilities of HeLa cells in comparison with Iressa-treated
cells and wild type cells. We found that SKI-606 and Iressa
aﬀect cell migration and invasion of SiHa cells at the same
level of HeLa cells. Next, we investigated the expression
pattern of E-cadherin and α-, β-, and γ-catenin using
Western blot and immunoﬂuorescence methods in HeLa
cells, untreated and treated with SKI-606 and Iressa. Using
Western blot analysis, we found that SKI-606 slightly up-
regulate the expression of the E-cadherin/catenin complex
(data not shown). Immunoﬂuorescence analysis results were
consistentlycorrelatedwithcellphenotypeaswellasinvasion
and migration; following SKI-606 treatment, typical cell-
cell adhesion type staining for E-cadherin and α-, β-, as
well as γ-catenin was observed on cell surfaces and the
undercoat membrane in HeLa cells converted to an epithelialJournal of Oncology 5
Control SKI-606 Iressa
HeLa
SiHa
Figure 3: SKI-606 and Iressa (to a lesser extent) induce morphological changes in HeLa and SiHa cell lines. Untreated (control) cells possess
a ﬁbroblast-like (mesenchymal) cell phenotype, whereas 48 hours treatment with SKI-606 (5μM) signiﬁcantly induces a mesenchymal-
epithelial transition of these cells in comparison with Iressa-treated cells.
Control SKI-606 Iressa
Figure 4: Eﬀect of SKI-606 and Iressa on colony formation ability of HeLa cell line. HeLa cells are able to form large colonies in soft agar.
In contrast, SKI-606 inhibits the colony formation ability of HeLa (P<. 0001) and SiHa cells (data not shown) in soft agar, whereas, Iressa
slightly reduce the colony formation following treatment with 5μM as described in the Materials and Methods section. Magniﬁcation is
100x. We have obtained the same results using SiHa cell line.
phenotype (Figure 6). In contrast, untreated cells and, to a
lesser extent, those treated with Iressa showed a weak and
diﬀused cytoplasmic and nuclear staining, with complete
loss of membrane localization of E-cadherin and catenins
(Figure 6).
To determine the role of Src/Abl inhibitor on the
regulation pattern genes of cell invasion and migration, we
examined the eﬀect of SKI-606 on gene expression patterns
of P-cadherin, fascin, Id-1, IGF-R1, and EGF-R, which are
important initiators of cell invasion and motility in several
human carcinomas including cervical, using Western blot
analysis. We found that SKI-606 signiﬁcantly decrease the
expression of P-cadherin, fascin, Id-1, and IGF-R1 in HeLa
cells in comparison with untreated cells and Iressa-treated
cells which are only slightly aﬀected (Figure 7(a)); moreover,
SKI-606 and Iressa (to a larger extent) reduce the expression
of EGF-R in comparison with control cells (Figure 7(a)).
RegardingthemechanismofE-cadherin/catenincomplexre-
localizationandP-cadherin,fascin,Id-1,IGF-R1,andEGF-R
gene deregulations, we hypothesized that SKI-606 provokes
E-cadherin/catenin complex reassociation by blocking the
phosphorylation of β-catenin through the inhibition of
pp60(c-Src) kinase phosphorylation in HeLa cancer cells.
Using SKI-606, we recently demonstrated that β-catenin
is physically associated with activated pp60(c-Src) kinase
and constitutively phosphorylated in human colorectal and
breast cancer cells [24, 27]. To assess this possibility in
cervical cancer cells, we examined the eﬀect of SKI-606 on6 Journal of Oncology
Cell invasion
Cell invasion
Cell motility
Control
Control Iressa SKI-606
SKI-606
Iressa 0
50
100
150
200
∅
∅
N
u
m
b
e
r
o
f
i
n
v
a
s
i
v
e
c
e
l
l
s
p
e
r
ﬁ
e
l
d
(
X
1
0
)
Figure 5: Comparison of SKI-606 and Iressa activity against cell migration and invasion ability of the HeLa cell line. SKI-606 and, to a
lesser extent, Iressa block cell migration at the same concentrations, as indicated in Materials and Methods, (arrows) within 48 hours in
comparison with untreated (control), (P<. 001) using a cell wounding assay. In parallel, SKI-606 dramatically inhibits cell invasion ability
of HeLa and SiHa cells (data not shown) in comparison with Iressa-treated and untreated (control) cells (arrows indicate invasive cells),
(P<. 0001) using Boyden chambers. Experiments conducted on SiHa cells showed the same data regarding cell migration and invasion
ability.
β-catenin regulation patterns in HeLa cancer cells. The cells
were treated for 48 hours with 5μMo fS K I - 6 0 6a n dI r e s s a
and then immunoprecipitated with anti-β-catenin. Western
blot analysis with antiphosphotyrosine revealed that β-
catenin is dephosphorylated in SKI-606-treated cells in com-
parison with untreated and Iressa-treated cells in which this
parameter is only slightly aﬀected (Figure 7(b)). In parallel,
we found that SKI-606 inhibits β-catenin phosphorylation
and consequently its translocation to the nucleus in these
cells (Figure 6); thus, SKI-606 blocks cell migration through
the conversion of β-catenin’s role from a transcriptional
regulator to a cell-cell adhesion function in HeLa-cervical
cancer cells and by modulating the expression patterns of
many genes including P-cadherin, fascin, Id-1, IGF-R1, and
EGF-R (Figure 7(a)).
4. Discussion
In this study, we examined the eﬀect of Src/Abl kinase
inhibitor on two human cervical cancer cells. Src kinases
are transducers of signals activated by many diﬀerent classes
of cell-surface receptors; more speciﬁcally, Src can be acti-
vated by growth factor receptors including ErbB and IGF-
receptors, cytokine receptors, protein tyrosine phosphatase
1B, CAS, and focal adhesion kinase (FAK). In addition,
Src interacts with a network of intracellular signaling path-
ways, including the integrin/FAK pathway, β-catenin/Wnt,
RAS-MEK, phosphatidylinositol-3-OH kinase-AKT and
Janus-activated kinase-STAT pathways [28–30]. These com-
plex interactions explain why Src is involved in a large num-
berofcellularfunctions.Thishaspromptedthedevelopment
of a number of small-molecule Src kinase inhibitors and
tyrosine kinase inhibitor (TKI) of ErbB-receptors, such as
SKI-606andIressa,whichcouldbeusedtotreatpatientswith
metastaticcancers.SeveralstudieshaverevealedthatSKI-606
inhibits cell proliferation and blocks cell cycle progression,
invasion and migration of several invasive human cancers
including breast, colon and nonsmall lung cancer cells [23–
25]. In parallel, numerous investigations found that Iressa
decreases cell invasion and tumor formation of human
cancer cells in vitro and in vivo [31–35]. In this paper, we
report that Src/Abl and, to a lesser extent, EGF-R inhibitor
decrease cell proliferation of two human cervical cancer cell
lines, which is accompanied by a deregulation of cell cycle
progression, particularly G0-G1 cell cycle. Therefore, these
inhibitors down-regulate cyclin D1, D2, and D3 as well as
their catalytic partners Cdk4 and Cdk6. We have recently
found that D-type cyclins (D1, D2 and D3) as well as their
catalytic partners Cdk4 and Cdk6 are downstream targets
of cellular transformation induced by E6/E7 of HPV type
16 in mouse normal embryonic ﬁbroblast cells ([21, 36, 37]
and unpublished data). Herein, we demonstrate, for the
ﬁrst time, that SKI-606 and, to a lesser extent, Iressa block
cell invasion and migration as well as colony formationJournal of Oncology 7
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Figure 6: Immunoﬂuorescence analysis of E-cadherin, α-, β-, and γ-catenin expression in HeLa-untreated (control) and SKI-606 as well as
Iressa-treated cells. We note that SKI-606-treatment restores the expression patterns of E-cadherin and α-, β-, as well as γ-catenin, on cell
surfaces and undercoat membrane, at 5 μM concentration, in HeLa cells when compared with Iressa-treated and untreated cells at the same
concentrations.
in soft agar of HeLa and SiHa human cervical cancer cell
lines which express E6/E7 oncoproteins of high-risk HPV
types 18 and 16, respectively. In parallel, we reveal that SKI-
606 and, to a lesser extent, Iressa, induces diﬀerentiation to
an epithelial phenotype of HeLa and SiHa human cervical
cancer cell lines; moreover, we report that Src/Abl inhibitor
up-regulates and restores the expression patterns of E-
cadherin as well as α-, β-, and γ-catenin in HeLa cells
in comparison with untreated cells and Iressa-treated cells
in which these parameters are less substantially aﬀected.
OtherstudiesfoundthatSKI-606inducesanover-expression
of E-cadherin in human breast cancer cells [23]. Recently,
Vultur et al. [38]demonstratedthatSrc/Ablinhibitorreduces
cell invasion and migration abilities of primary human
breastcancercellsbyincreasingmembrane-localizationofE-
cadherin and β-catenin.
It is well established that high-risk HPV infection plays
an important role in the progression of human cervical
cancer. Moreover, the presence of high-risk HPVs has been
shown to serve as prognostic factors in early-stage cervical
cancer, and is associated with vascular invasion, lymph node
metastases, and tumor size [7, 39, 40]. Nevertheless, during
high-risk HPV infection, E6/E7 oncoproteins are expressed
and, as a result, the restraint on cell-cycle progression is
abolished and normal terminal diﬀerentiation is retarded
[41]. Therefore, E6/E7 of high-risk HPV can deregulate
several oncogenes, such as P-cadherin, fascin, Id-1, IGF-R1,
and EGF-R which are known to enhance the progression
of human cervical cancer [42–46]. In the present study,
we provide evidence that SKI-606 and, to a lesser extent,
Iressa inhibit cell invasion and migration of HeLa and SiHa
cancer cells; this is accompanied by a downexpression of P-
cadherin, fascin, Id-1, IGF-R1 and EGF-R. Consequently, the
inhibition of cell invasion and migration by this Src inhibitor
is related to the downregulation of those genes and probably
other oncogenes that might be involved in this process
throughβ-catenin’sroleconversioninhumancervicalcancer
cells expressing E6/E7 oncoproteins of high-risk HPV. We
have recently reported that β-catenin is physically associated
and activated by pp60(c-Src) kinase and is constitutively
phosphorylated on the tyrosine residue in human colorectal
and breast cancer cells [24, 27]; therefore, Src activation8 Journal of Oncology
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Figure 7: Comparison between the inﬂuence of SKI-606 and
Iressa activity on P-cadherin, fascin, Id-1, IGF-R1, and EGF-R
expression as well as β-catenin phosphorylation in HeLa cells.
(a) Western blot analysis of P-cadherin, fascin, Id-1, IGF-R1, and
EGF-R expression in HeLa-untreated and treated cells. We found
that SKI-606 decreases the expression of P-cadherin, fascin, Id-
1 and IGF-R1 in HeLa cells in comparison with Iressa-treated
(as indicated in the Materials and Methods) and untreated cells;
in contrast, Iressa largely reduces the expression of EGF-R in
comparison with SKI-606. (b) Tyrosine phosphorylation analysis of
β-catenin in HeLa cells and SKI-606 as well as Iressa-treated cells.
Src/Ablinhibitor(SKI-606)blockstheconstitutivephosphorylation
of Src and consequently β-catenin phosphorylation in HeLa cancer
cells. Cells were grown for two days in both the absence (control)
and presence of 2 and 5μM of SKI-606 and 5μM of Iressa. Cell
lysates were immunoprecipitated with anti-β-catenin antibody and
analyzed by immunoblotting with antiphosphotyrosine antibody as
described in Section 2.
converts β-catenin’s role from a cell-cell adhesion molecule
to a transcriptional regulator via its interaction with the
Tcf/Lef family of transcription factors [47, 48]. Our present
data show that Src/Abl inhibitor restores the expression
of β-catenin to the undercoat membrane to act as a cell-
cell molecule which can deregulate several genes including
P-cadherin, fascin, Id-1, IGF-R1 and EGF-R; thus, these
deregulations induce cell diﬀerentiation and consequently
block cell invasion ability of these human cervical cancer
cells.
In conclusion, our study is the ﬁrst evidence demon-
strating that treatment with Src/Abl inhibitor and, to a
lesser extent, EGF-R inhibitor induce diﬀerentiation to an
epithelial phenotype and upregulates as well as restores
the expression of the E-cadherin/catenin complex and
subsequently inhibits cell invasion and migration of human
cervical cancer cells. These observations are accompanied
by downregulation of several important regulators of cell
invasion and metastasis. Thus, this investigation has several
clinical implications. First and most importantly, it points
toward a new mechanism of action for Src inhibitors and
suggests the use of P-cadherin, fascin, Id-1, IGF-R1 and
EGF-R as biomarkers. Second, we speculate that therapeutic
strategies based on Src inhibitor can dramatically reduce
human tumor recurrence and metastasis. Beyond this, based
on the implication of Src and β-catenin in human carcino-
genesis, the ﬁndings described in the present report may
lead to advances in the biology and treatment of malignant
cervical carcinomas which are positive for high risk HPVs.
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